Clinical trial · Interventional
Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer
A Pilot Study of Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer
NCT01717482CI-TRIAL-00043925terminatedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Poor accrual and funding ended
Summary
Brief summary (as posted)
The purpose of this study is to learn whether it is better to receive the drug Metformin with standard of care for lung cancer or just standard of care.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Metformin | Drug | Metformin | ALIAS |
| Placebo Comparator | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Metformin
- description
- Metformin 850mg twice a day
- interventionNames
- Drug: Metformin
- type
- PLACEBO_COMPARATOR
- label
- Observation
- description
- Standard of Care Observation
- interventionNames
- Other: Placebo Comparator
Primary outcomes (2)
- measure
- Evaluate Feasibility of Patient Randomization, Accrual, and Tissue Collection for Study Conduction
- timeFrame
- 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria * Suspected or biopsy proven Stage IA-IIIA lung squamous cell carcinoma (SCC) (must be proven SCC at the time of surgery) * Medically fit for surgical resection (based on surgeon assessment) * Current or prior smoker * Age \> 18 years old * Both Male and Female * Willing and able to consent to study, undergo study interventions, and take study drug * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2 * Subject must start Metformin within 90 days of surgery. Exclusion Criteria * Currently taking metformin or other diabetic drugs * Current or previous congestive heart failure, renal failure or liver failure * Creatinine in Women of 1.4 or greater and Creatinine in Men of 1.5 or greater * Existing untreated or prior cancer \<5 years from diagnosis * Received neo-adjuvant platinum-based chemotherapy or targeted therapy * Receiving adjuvant platinum-based chemotherapy or targeted therapy after surgical resection
References
Publications (0)
Data not yet available
No reference posted for this study.